JP5386508B2 - インドリル−ピリドン誘導体類 - Google Patents

インドリル−ピリドン誘導体類 Download PDF

Info

Publication number
JP5386508B2
JP5386508B2 JP2010543556A JP2010543556A JP5386508B2 JP 5386508 B2 JP5386508 B2 JP 5386508B2 JP 2010543556 A JP2010543556 A JP 2010543556A JP 2010543556 A JP2010543556 A JP 2010543556A JP 5386508 B2 JP5386508 B2 JP 5386508B2
Authority
JP
Japan
Prior art keywords
title compound
carboxylic acid
oxo
dihydro
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010543556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510055A (ja
JP2011510055A5 (enExample
Inventor
ストークス，スティーブン
フォロップ，ニコラ
フィウマーナ，アンドレア
ドライスデール，マーティン
ベッドフォード，サイモン
ウェッブ，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0801090.2A external-priority patent/GB0801090D0/en
Priority claimed from GBGB0818695.9A external-priority patent/GB0818695D0/en
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JP2011510055A publication Critical patent/JP2011510055A/ja
Publication of JP2011510055A5 publication Critical patent/JP2011510055A5/ja
Application granted granted Critical
Publication of JP5386508B2 publication Critical patent/JP5386508B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010543556A 2008-01-22 2009-01-20 インドリル−ピリドン誘導体類 Expired - Fee Related JP5386508B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0801090.2 2008-01-22
GBGB0801090.2A GB0801090D0 (en) 2008-01-22 2008-01-22 New chemical compounds
GBGB0818695.9A GB0818695D0 (en) 2008-10-11 2008-10-11 New chemical compounds
GB0818695.9 2008-10-11
PCT/GB2009/000149 WO2009093012A1 (en) 2008-01-22 2009-01-20 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity

Publications (3)

Publication Number Publication Date
JP2011510055A JP2011510055A (ja) 2011-03-31
JP2011510055A5 JP2011510055A5 (enExample) 2012-03-01
JP5386508B2 true JP5386508B2 (ja) 2014-01-15

Family

ID=40377594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543556A Expired - Fee Related JP5386508B2 (ja) 2008-01-22 2009-01-20 インドリル−ピリドン誘導体類

Country Status (17)

Country Link
US (5) US8916591B2 (enExample)
EP (1) EP2294065B1 (enExample)
JP (1) JP5386508B2 (enExample)
CN (1) CN101970424B (enExample)
AU (1) AU2009207478B2 (enExample)
BR (1) BRPI0906495B8 (enExample)
CA (1) CA2712959C (enExample)
DK (1) DK2294065T3 (enExample)
EA (1) EA021464B1 (enExample)
ES (1) ES2461799T3 (enExample)
IL (1) IL206808A (enExample)
MX (1) MX2010007525A (enExample)
NZ (1) NZ586756A (enExample)
PL (1) PL2294065T3 (enExample)
PT (1) PT2294065E (enExample)
WO (1) WO2009093012A1 (enExample)
ZA (1) ZA201005210B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970424B (zh) 2008-01-22 2013-06-12 弗奈利斯（R&D）有限公司 具有检测点激酶1抑制活性的吲哚基吡啶酮衍生物
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
JP6161537B2 (ja) 2010-04-07 2017-07-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
RU2638552C2 (ru) 2011-09-27 2017-12-14 Ф. Хоффманн-Ля Рош Аг Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
TN2017000329A1 (en) * 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
MX2020005515A (es) * 2017-12-19 2020-09-03 Bristol Myers Squibb Co Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
SG11202100158WA (en) * 2018-07-24 2021-02-25 Epizyme Inc Pyridin-2-one compounds useful as smarca2 antagonists
US10253606B1 (en) 2018-07-27 2019-04-09 Upwing Energy, LLC Artificial lift
US10370947B1 (en) * 2018-07-27 2019-08-06 Upwing Energy, LLC Artificial lift
US10787873B2 (en) 2018-07-27 2020-09-29 Upwing Energy, LLC Recirculation isolator for artificial lift and method of use
US10280721B1 (en) 2018-07-27 2019-05-07 Upwing Energy, LLC Artificial lift
EP3842425B1 (en) * 2018-08-24 2024-05-22 TransThera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
US11686161B2 (en) 2018-12-28 2023-06-27 Upwing Energy, Inc. System and method of transferring power within a wellbore
CN112625027B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 杂环衍生物及其用途
WO2023250141A2 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency
CN115594634B (zh) * 2022-10-26 2024-10-01 浙江工业大学 一种连续化制备4-硝基吡唑的新工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030083016A (ko) * 2001-03-28 2003-10-23 브리스톨-마이어스스퀴브컴파니 신규 타이로신 카이나제 억제제
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
AU2004251175A1 (en) 2003-06-05 2005-01-06 Merck & Co., Inc. Substituted indoles and a process for preparing substituted indoles
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2006324144A1 (en) * 2005-01-28 2007-08-02 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2006134318A1 (en) 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
EP2046330A2 (en) * 2006-07-14 2009-04-15 Astex Therapeutics Limited Pharmaceutical combinations
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
CN101970424B (zh) 2008-01-22 2013-06-12 弗奈利斯（R&D）有限公司 具有检测点激酶1抑制活性的吲哚基吡啶酮衍生物
EA201101619A1 (ru) * 2009-05-15 2012-05-30 Новартис Аг Производные 5-пиридин-3-ил-1,3-дигидроиндол-2-она и их применение в качестве модуляторов альдостеронсинтазы и/или cyp11b1

Also Published As

Publication number Publication date
DK2294065T3 (da) 2014-04-28
ZA201005210B (en) 2011-03-30
US10696652B2 (en) 2020-06-30
ES2461799T3 (es) 2014-05-21
AU2009207478A1 (en) 2009-07-30
US20170298043A1 (en) 2017-10-19
CA2712959A1 (en) 2009-07-30
IL206808A (en) 2015-08-31
BRPI0906495B1 (pt) 2020-11-10
CN101970424B (zh) 2013-06-12
WO2009093012A1 (en) 2009-07-30
EP2294065A1 (en) 2011-03-16
US8916591B2 (en) 2014-12-23
EA021464B1 (ru) 2015-06-30
JP2011510055A (ja) 2011-03-31
PL2294065T3 (pl) 2014-11-28
AU2009207478B2 (en) 2013-11-21
NZ586756A (en) 2012-04-27
BRPI0906495A2 (pt) 2015-07-14
US20110021498A1 (en) 2011-01-27
US20200361905A1 (en) 2020-11-19
US20150099736A1 (en) 2015-04-09
PT2294065E (pt) 2014-05-15
MX2010007525A (es) 2010-08-18
CN101970424A (zh) 2011-02-09
US20180244652A1 (en) 2018-08-30
CA2712959C (en) 2015-06-23
IL206808A0 (en) 2010-12-30
BRPI0906495A8 (pt) 2015-10-06
EA201001197A1 (ru) 2011-04-29
US9604975B2 (en) 2017-03-28
BRPI0906495B8 (pt) 2021-05-25
EP2294065B1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
JP5386508B2 (ja) インドリル−ピリドン誘導体類
CN114867720B (zh) 杂芳基类衍生物及其制备方法和用途
CN106170288B (zh) 药物化合物
CN114761086A (zh) 作为parp7抑制剂的哒嗪酮
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
CN102471314B (zh) 适合于特别是睡眠障碍和药物成瘾的治疗的螺氨基化合物
KR20120097410A (ko) 베타－트립타제 억제제로서의 인돌릴－피페리디닐 벤질아민
TW202322811A (zh) Parp-1降解劑及其用途
KR20230173234A (ko) 인다졸계 화합물 및 관련된 사용 방법
WO2022166974A1 (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN113968856A (zh) 一类具有激酶抑制活性的化合物
EP3083597B1 (en) Fluoromethyl-substituted pyrrole carboxamides as cav2.2 calcium channel blockers
WO2024151638A2 (en) Compounds for fgfrs inhibitors
CN120835881A (zh) 能够降解雄激素受体的双官能化合物
CN116917279A (zh) Btk抑制剂
CN100436445C (zh) 吡唑衍生物
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
WO2025034912A9 (en) Compounds for fgfr inhibition
WO2011010083A1 (en) Indolyl-pyridone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131007

R150 Certificate of patent or registration of utility model

Ref document number: 5386508

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees